Tag: Xeltis
Xeltis announces US FDA Breakthrough Device Designation for aXess and first...
Xeltis has today announced that the Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA) has granted aXess...
Xeltis expands leadership team with appointment of Luc Verhees as vice...
Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces that it has appointed Luc Verhees...
Xeltis appoints Shawn Gage as vice president of US clinical affairs
Xeltis has announced today the appointment of Shawn Gage as its new vice president of US clinical affairs. The company stated that his appointment...
Renal Interventions’ top 10 stories of June 2024
The month of June gave us insight into the future of standard-of-care, updates from meetings, and what can be achieved “with a bit of...
Xeltis receives IDE approval from US FDA for haemodialysis vascular access...
Xeltis has announced that it has gained approval from the US Food and Drug Administration (FDA) for an investigational device exemption (IDE) submission to...
Twelve-month first-in-human data from Xeltis’ aXess haemodialysis vascular conduit trial presented...
Xeltis has announced "highly encouraging" 12-month results from its first-in-human (FIH) aXess vascular conduit trial. The data were presented by Frans Moll (University Medical...
Xeltis secures additional €12.5 million from European Innovation Council
Xeltis has announced the closing of an additional €12.5 million in funding from the European Innovation Council (EIC) Fund, set up by the European...
Xeltis presents six-month first-in-human data on aXess graft
Xeltis has presented “highly-encouraging” six-month data from its first-in-human (FIH) aXess vascular graft trial at the 13th Congress of the Vascular Access Society (VAS;...
Xeltis secures funding to progress clinical trials
Xeltis has raised €32 million in a Series D2 equity fundraise, backed by a syndicate of current and new investors, which the company says...
The aXess vascular graft: Potentially fulfilling a major unmet clinical need...
This advertorial is sponsored by Xeltis.
An de Vriese (Bruges, Belgium), who is playing a leading role in an ongoing European trial investigating the aXess...
Xeltis starts pivotal clinical trial of “first-ever” restorative synthetic haemodialysis access...
Xeltis announced today the initiation of a pivotal trial with the “first-ever” restorative synthetic haemodialysis access grafts, dubbed ‘Axess’.
The first two patients have been...
Xeltis presents “promising” first-in-human data on restorative haemodialysis access graft
Xeltis today announced what it describes as “very promising” preliminary efficacy and safety results from one of the centres participating in the AXESS study—a...
Restorative Axess graft demonstrates promising patency and safety in first-in-human study
The preliminary results from a clinical trial assessing a restorative haemodialysis access graft have shown promising early puncturing, patency and safety data. These findings...
A raft of new directions for vascular access grafts
A departure from the “extreme mantra” of Fistula First unlocks the door to a new, dynamic vision that could swing the pendulum back to...
Xeltis announces “promising outcomes” in restorative graft trials following EU financing
Xeltis has announced promising initial outcomes from two key vascular trials involving its restorative graft technologies.
According to the company, more than 350 successful dialysis...
Xeltis initiates European first-in-human trial of restorative haemodialysis access graft
Xeltis has announced initiation of a clinical trial evaluating Axess, which it claims is the first ever restorative synthetic haemodialysis access graft. Several patients...